Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that the Journal of Clinical Oncology® (An American Society of Clinical Oncology Journal) has selected the company’s GEN-009 clinical results presentation at the 2019 ASCO Annual Meeting as a top 10 featured abstract in immuno-oncology. The full poster will be available on the Genocea website here concurrent with its presentation tomorrow:
ASCO 2019 POSTER SESSION: Developmental Immunotherapy and Tumor Immunobiology
Poster Board: #255 • Abstract 2611
Poster Board: #255 • Abstract 2611
| Title: | A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses | ||
| Presenters: | Roger B. Cohen, M.D., University of Pennsylvania Perelman School of Medicine and principal investigator in the trial, and Przemyslaw W. Twardowski, M.D., John Wayne Cancer Institute | ||
| Date: | Saturday, June 1, 8:00 AM – 11:00 AM Central Time | ||
| Location: | Hall A |
Conference Call and Webcast – Monday, June 3rd at 8:30 am ETGenocea will host a conference call and webcast to discuss the clinical results presented at ASCO at 8:30 am ET on Monday, June 3, 2019. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 9068006. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations. A webcast replay of the conference call will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.